These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pulmonary toxicity associated with fludarabine monophosphate. Hurst PG; Habib MP; Garewal H; Bluestein M; Paquin M; Greenberg BR Invest New Drugs; 1987; 5(2):207-10. PubMed ID: 2443463 [TBL] [Abstract][Full Text] [Related]
6. [Phase II clinical study of SH L 573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia]. Miyawaki S; Imamura M; Kobayashi S; Ohnishi K; Hodohara K; Mizoguchi H; Tomonaga M; Tango T; Ohno R Rinsho Ketsueki; 1999 Dec; 40(12):1236-44. PubMed ID: 10658476 [TBL] [Abstract][Full Text] [Related]
7. Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia. Bastion Y; Coiffier B; Tigaud JD; Espinouse D; Bryon PA Eur J Cancer; 1991; 27(5):671. PubMed ID: 1711356 [No Abstract] [Full Text] [Related]
8. Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis. Cervantes F; Salgado C; Montserrat E; Rozman C Lancet; 1990 Nov; 336(8723):1130. PubMed ID: 1700245 [No Abstract] [Full Text] [Related]
10. [Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma]. Arima N; Mizoguchi H; Shirakawa S; Tomonaga M; Takatsuki K; Ohno R Gan To Kagaku Ryoho; 1999 Apr; 26(5):619-29. PubMed ID: 10234292 [TBL] [Abstract][Full Text] [Related]
11. Tumor lysis syndrome induced by fludarabine monophosphate: a case report. Nakhoul F; Green J; Abassi ZA; Carter A Eur J Haematol; 1996 Apr; 56(4):254-5. PubMed ID: 8641396 [No Abstract] [Full Text] [Related]
12. Fludarabine monophosphate as salvage for refractory chronic lymphocytic leukaemia. Pillay GS; Wood L; Jacobs P S Afr Med J; 1996 Aug; 86(8):949-51. PubMed ID: 8823419 [TBL] [Abstract][Full Text] [Related]
13. [Fludarabine monophosphate in the treatment of patients with advanced stages of chronic B-cell lymphatic leukemia resistant to conventional chemotherapy]. Papajík T; Faber E; Hubácek J; Slezák P; Raida L; Heczko M; Sulovská I; Jarosová M; Pikalová Z; Indrák K Vnitr Lek; 1997 Jan; 43(1):25-8. PubMed ID: 9221561 [TBL] [Abstract][Full Text] [Related]
14. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. Keating MJ; Kantarjian H; O'Brien S; Koller C; Talpaz M; Schachner J; Childs CC; Freireich EJ; McCredie KB J Clin Oncol; 1991 Jan; 9(1):44-9. PubMed ID: 1702145 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. Rossi JF; van Hoof A; de Boeck K; Johnson SA; Bron D; Foussard C; Lister TA; Berthou C; Kramer MH; Littlewood TJ; Marcus RE; Deconinck E; Montillo M; Guibon O; Tollerfield SM J Clin Oncol; 2004 Apr; 22(7):1260-7. PubMed ID: 15051774 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of fludarabine phosphate in renal cell carcinoma: a Southwest Oncology Group Study. Balducci L; Blumenstein B; Von Hoff DD; Davis M; Hynes HE; Bukowski RM; Crawford ED Cancer Treat Rep; 1987 May; 71(5):543-4. PubMed ID: 2436773 [No Abstract] [Full Text] [Related]